Longwood Capital Partners »

Avalo Therapeutics Ord shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Avalo Therapeutics Ord (AVTX) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Avalo Therapeutics Ord

Tip: Access up to 7 years of quarterly data

All positions including Avalo Therapeutics Ord held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Avalo Therapeutics Ord by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $908k 61k 14.93

More positions owned by Longwood Capital Partners

Ideaya Biosciences Call Call Option (IDYA)
Praxis Precision Medicines I Com New (PRAX)
Terns Pharmaceuticals (TERN)
Aadi Bioscience (WHWK)
Tango Therapeutics (TNGX)
Bright Minds Biosciences Com New (DRUG)
Sutro Biopharma (STRO)
Erasca (ERAS)
Surrozen Com New (SRZN)
Ocular Therapeutix (OCUL)
Compass Therapeutics (CMPX)
Minerva Neurosciences Com New (NERV)
Moonlake Immunotherapeutics Class Ord A (MLTX)
Argen Se - Sponsored Adr (ARGX)
Oculis Holding Ordinary Shares (OCS)

View all positions for Longwood Capital Partners

Top funds holding Avalo Therapeutics Ord

BVF
Logos Global Management
Nantahala Capital Management
UBS Group
Affinity Asset Advisors
Point72 Asset Management
Caligan Partners
Millennium Management
Vanguard Group
TCG Crossover Management
Balyasny Asset Management
Vanguard Capital Management
RA Capital Management
Bank of America Corporation
Ikarian Capital

View all funds holding Avalo Therapeutics Ord